Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

3

Investigational

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

DNA

1

Serine/threonine-protein kinase Chk1

1

Serine/threonine-protein kinase Chk2

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

1

Phase III

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1978

1

2014

1

2023

1

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Advanced bladder cancer

1

Breast cancer

1

Castrate-resistant prostate cancer

1

Metastatic ovarian tumors

1

Metastatic testicular tumors

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Array BioPharma

1

Peyrone, M.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

Protein

2

All Match

Any Match

Exclude Selected

Exclude Selected

INN Stem

Monoclonal antibodies(-mab)

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

4

FDA ORPHAN DRUG

4

FDA UNII

4

DAILYMED

3

INN

3

All Match

Any Match

Exclude Selected

Exclude Selected

Protein Type

MONOCLONAL ANTIBODY

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTINEOPLASTIC AGENTS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER ANTINEOPLASTIC AGENTS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Monoclonal antibodies

1

Platinum compounds

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

3

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "ORPHAN DRUG|Designated|Treatment of anal cancer" in comments (approximate match)

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CISPLATIN

Q20Q21Q62J

Export Data
Search for Structure

Status:

US Approved Rx (1978)

First approved in 1978

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Conditions:

Advanced bladder cancer

Metastatic ovarian tumors

Metastatic testicular tumors

Non-small cell lung cancer

Platinous chloride is used as a catalyst in organic synthesis. The salt is insoluble in water.

RETIFANLIMAB

2Y3T5IF01Z

Subunit 1 (445) Similarity Search Subunit 2 (445) Similarity Search Subunit 3 (218) Similarity Search Subunit 4 (218) Similarity Search

Export Data
Sequence Search

Subunit 1 (445) Similarity Search Subunit 2 (445) Similarity Search Subunit 3 (218) Similarity Search Subunit 4 (218) Similarity Search

Status:

US Approved Rx (2023)

First approved in 2023

Class:

PROTEIN

NIVOLUMAB

31YO63LBSN

Subunit 1 (440) Similarity Search Subunit 2 (440) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Export Data
Sequence Search

Subunit 1 (440) Similarity Search Subunit 2 (440) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Status:

US Approved Rx (2014)

First approved in 2014

Class:

PROTEIN

PREXASERTIB MESYLATE MONOHYDRATE

S4D3L195S4

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Serine/threonine-protein kinase Chk2

Serine/threonine-protein kinase Chk1

Conditions:

Small-cell lung cancer

Castrate-resistant prostate cancer

LY2606368 (Prexasertib) is a small-molecule Chk-1 inhibitors invented by Array and being developed by Eli Lilly and Company. Lilly is responsible for all clinical development and commercialization activities. LY2606368 is advancing in Phase 2 clinica...

l trials for cancer. Prexasertib preferentially binds to and inhibits CHK1 and, to a lesser extent, inhibits CHK2. Chk-1 is a protein kinase that regulates the tumor cell's response to DNA damage often caused by treatment with chemotherapy. In response to DNA damage, Chk-1 blocks cell cycle progression in order to allow for repair of damaged DNA, thereby limiting the efficacy of chemotherapeutic agents. Inhibiting Chk-1 in combination with chemotherapy can enhance tumor cell death by preventing these cells from recovering from DNA damage.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1